2. Vías de señalización
  3. Antibody-drug Conjugate/ADC Related
  4. Drug-Linker Conjugates for ADC

Drug-Linker Conjugates for ADC

ADC-Related Custom Services

Drug-Linker Conjugates for ADC

Related Products

PDF 0.45 MB

Drug-Linker Conjugates for Antibody Drug Conjugates (ADCs) comprise of an active cytotoxic drug and an appropriate linker. After linked to a monoclonal antibody, those conjugates can be used for making ADCs, which are targeted agents for cancer cells with high selectivity and cytotoxicity.

The drug units in drug-linker conjugates are cytotoxic agents (i.e. ADC cytotoxins or payloads) with antitumor activity and can be classified in DNA damaging agents and tubulin inhibitors. The most commonly used DNA damaging agents in ADCs are Duocarmycins, Pyrrolobenzodiazepines, Camptothecins and Daunorubicins/Doxorubicins, while the popular tubulin inhibitors are Auristatins and Maytansinoids. Besides, there are also many traditional cytotoxic agents can be used in ADCs.

ADC linkers currently undergoing clinical evaluation are mostly classified into two categories: cleavable and noncleavable. Cleavable linkers rely on processes inside the cell to liberate the toxin, and noncleavable linkers require proteolytic degradation of the antibody portion of the ADC for release of the cytotoxic molecule.

Drug-Linker Conjugates for ADC Isoform Specific Products:

Drug-Linker Conjugates for ADC Isoform Comparison
Cat. No. Nom du produit Effet Pureté Chemical Structure
  • HY-170868
    CL2A-FL118
    CL2A-FL118 is a drug-linker for synthesis of ADC molecule Sac-CL2A-FL118.
    CL2A-FL118
  • HY-136260
    DBCO-PEG4-Ahx-DM1
    DBCO-PEG4-Ahx-DM1 is a agent-linker conjugate composed of a potent microtubulin inhibitor DM1 and a linker DBCO-PEG4-Ahx to make antibody agent conjugate (ADC). Mertansine (DM1) is a microtubulin inhibitor and is an antibody-conjugatable maytansinoid that is developed to overcome systemic toxicity associated with maytansine and to enhance tumor-specific delivery. DBCO-PEG4-Ahx-DM1 is a click chemistry reagent, it contains a DBCO group that can undergo strain-promoted alkyne-azide cycloaddition (SPAAC) with molecules containing Azide groups.
    DBCO-PEG4-Ahx-DM1
  • HY-100374G
    Val-Cit-PAB-MMAE (GMP)
    Val-Cit-PAB-MMAE GMP is a GMP grade Val-Cit-PAB-MMAE (HY-100374). Val-Cit-PAB-MMAE is a agent-linker conjugate for ADC. Val-Cit-PAB-MMAE contains the ADCs linker (peptide Val-Cit-PAB) and a potent tubulin inhibitor MMAE (HY-15162). MMAE a potent mitotic inhibitor by inhibiting tubulin polymerization.
    Val-Cit-PAB-MMAE (GMP)
  • HY-178293
    N-Succinimidyl 3-maleimidopropionate
    		98.53%
    N-Succinimidyl 3-maleimidopropionate (Compound MC1) is a Glucuronide-Gemcitabine conjugate. N-Succinimidyl 3-maleimidopropionate can be used to synthesize ADCs (such as cAc10ec-MC1). N-Succinimidyl 3-maleimidopropionate can be used in Hodgkin's lymphoma research.
    N-Succinimidyl 3-maleimidopropionate
  • HY-128959
    MCC-Modified Daunorubicinol
    MCC-Modified Daunorubicinol is a drug-Linker conjugates for ADC, which is composed of Modified Daunorubicinol (DNA topoisomerase II inhibitor) and MCC (ADC linker) linked.
    MCC-Modified Daunorubicinol
  • HY-164309
    DBCO-PEG3-Glu-Val-Cit-PABC-MMAE
    DBCO-PEG3-Glu-Val-Cit-PABC-MMAE is a drug-linker conjugate for ADC. DBCO-PEG3-Glu-Val-Cit-PABC-MMAE contains a potent tubulin inhibitor Monomethyl auristatin E (MMAE, HY-15162) and can be used for synthesis of dual-drug ADC.
    DBCO-PEG3-Glu-Val-Cit-PABC-MMAE
  • HY-136313
    MC-VC-PAB-Tubulysin M
    		98.26%
    MC-vc-PAB-Tubulysin M is a Drug-Linker Conjugates for ADC, consisting of a microtubule polymerization inhibitor Tubulysin M (an ADC cytotoxin) (HY-N7053) and MC-vc-PAB (a cleavable ADC linker).
    MC-VC-PAB-Tubulysin M
  • HY-173243A
    Val-Ala-PAB-SN38 TFA
    		98.22%
    Val-Ala-PAB-SN38 TFA is a drug-linker conjugate for ADC, composed of ADC linker Val-Ala-PAB (HY-125933) and SN38 (HY-13704), which is the active metabolite of the Topoisomerase I inhibitor Irinotecan (HY-16562).
    Val-Ala-PAB-SN38 TFA
  • HY-177683
    N-(DBCO-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan)
    N-(DBCO-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(DBCO-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
    N-(DBCO-PEG4)-N-(PEG4-Val-Cit-PAB-MMAE)-N-(PEG4-Val-Cit-PAB-Exatecan)
  • HY-176977
    Exatecan-mpGly-Asn-Asn-(βAla)
    Exatecan-mpGly-Asn-Asn-(βAla) (Compound 10b) is a conjugate of Exatecan (HY-13631) and a linker. Exatecan-mpGly-Asn-Asn-(βAla) can be used to synthesize ADCs, such as α-HER2_mpGlyAsnAsn(β-Ala)_Exatecan. Exatecan-mpGly-Asn-Asn-(βAla) can also be used in tumor research.
    Exatecan-mpGly-Asn-Asn-(βAla)
  • HY-157079
    LP-6
    LP-6 is a Drug-Linker Conjugate for ADC, and can be used for synthesis of ADCs. LP-6 consists of an Eg5 inhibitor and a linker.
    LP-6
  • HY-13631ES3
    Deruxtecan-d2
    Deruxtecan-d2 is the deuterium labeled Deruxtecan (HY-13631E). Deruxtecan is an ADC drug-linker conjugate composed of an DX-8951 derivative (DXd) and a maleimide-GGFG peptide linker, used for synthesizing DS-8201 and U3-1402.
    Deruxtecan-d<sub>2</sub>
  • HY-177681
    N-(Mal)-N-(PEG8-Val-Cit-PAB-MMAE)-N-(PEG8-Val-Cit-PAB-Exatecan)
    N-(Mal)-N-(PEG8-Val-Cit-PAB-MMAE)-N-(PEG8-Val-Cit-PAB-Exatecan) is a drug-linker conjugate for ADC (Drug-Linker Conjugate for ADC), consisting of a tubulin polymerization inhibitor MMAE (HY-15162) and a DNA topoisomerase I inhibitor Exatecan (HY-13631), and an ADC linker composition. N-(Mal)-N-(PEG8-Val-Cit-PAB-MMAE)-N-(PEG8-Val-Cit-PAB-Exatecan) can be used for synthesis of ADCs and for cancer research.
    N-(Mal)-N-(PEG8-Val-Cit-PAB-MMAE)-N-(PEG8-Val-Cit-PAB-Exatecan)
  • HY-177146
    Paclitaxel-MVCP
    Paclitaxel-MVCP (MC-Val-Cit-PAB-Paclitaxel) is a MC-Val-Cit-PAB (HY-78738) and Paclitaxel (HY-B0015) conjugate, and can be used for synthesis of Paclitaxel-nucleolin aptamer conjugate.
    Paclitaxel-MVCP
  • HY-128907
    MC-Val-Cit-PAB-clindamycin
    		99.99%
    MC-Val-Cit-PAB-clindamycin is a agent-linker conjugate for ADC with potent antitumor activity by using clindamycin (a protein synthesis inhibitor), linked via the ADC linker MC-Val-Cit-PAB.
    MC-Val-Cit-PAB-clindamycin
  • HY-155870B
    DL-01 TFA
    		99.23%
    DL-01 TFA is the TFA salt form of DL-01 (HY-155870). DL-01 TFA is a drug-linker conjugates for ADC that can be used for the synthesis of ADCs.
    DL-01 TFA
  • HY-141596
    Lys-Nε-SPDB-DM4
    		99.81%
    Lys-Nε-SPDB-DM4 is a agent-linker conjugate composed of a potent a tubulin inhibitor DM4 and a linker Lys-Nε-SPDB to make antibody agent conjugate (ADC).
    Lys-Nε-SPDB-DM4
  • HY-145989
    Aminobenzenesulfonic auristatin E
    Aminobenzenesulfonic auristatin E is a agent-linker conjugate for ADC. Aminobenzenesulfonic auristatin E has potent antitumor activity by using Auristatin E (a cytotoxic tubulin modifier), linked via the ADC linker Aminobenzenesulfonic.
    Aminobenzenesulfonic auristatin E
  • HY-164637
    Aniline-PEG3-C1-Boc
    Aniline-PEG3-C1-Boc (compound D-1) is an intermediate of cytotoxic drug linker polymer. Aniline-PEG3-C1-Boc can be used in the synthesis of antibody-drug conjugates (ADCs).
    Aniline-PEG3-C1-Boc
  • HY-164836
    Deruxtecan-Eribulin
    Deruxtecan-Eribulin is a Drug-Linker Conjugates for ADC, which is composed of a linker and a toxic molecule Exatecan (HY-13631) (DNA topoisomerase I inhibitor) and Eribulin (HY-13442) (Microtubule inhibitor). Deruxtecan-Eribulin can be used for ADC synthesis.
    Deruxtecan-Eribulin
Drug-Linker Conjugates for ADC Isoform Comparison

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.